Ocrevus is competing in a crowded market for MS drugs, but looks likely to have advantages over already marketed rivals. Along with strong efficacy figures in relapsing disease, trial evidence ...

Ocrevus (ocrelizumab) is a prescription drug that treats certain types of multiple sclerosis (MS) in adults by lowering B cell levels. Your response to this drug may vary based on your medical ...

Roche’s star multiple sclerosis (MS) drug Ocrevus (ocrelizumab) infusion has been approved in Europe, the first and only approved disease-modifying drug for a debilitating form of the disease.

Ocrevus, also known by its generic name ocrelizumab, is an immunotherapy drug commonly used to treat two types of multiple ...

TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite cash runway. Learn more on TGTX stock here.

Walk MS is two weeks away, and more than 1,500 people in the area are hard at work fundraising and building their teams.

GlobalData spotlighted Roche’s Ocrevus and Novartis’ Kesimpta as leaders ... Now, the success of MS drugs and psychiatry breakthroughs is flipping the narrative, reigniting investment in ...

The global central nervous system (CNS) market is projected grow to over $80 billion in sales in 2025 for the first time ...